Evaluation of Diagnostic Tests and Argatroban or Lepirudin Therapy in Patients with Suspected Heparin-Induced Thrombocytopenia
- 1 December 2005
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (12) , 1736-1745
- https://doi.org/10.1592/phco.2005.25.12.1736
Abstract
To evaluate diagnostic tests for heparin-induced thrombocytopenia (HIT), a serious drug reaction that can occur in patients receiving heparin, and to evaluate treatment with direct thrombin inhibitors-the only initial drug therapy that decreases the risk of thromboembolism associated with immune-mediated HIT. Retrospective cohort study. University teaching hospital. Patients with HIT treated with argatroban or lepirudin between January 1, 2000, and December 31, 2003. Patients were assessed for dosage and duration of argatroban or lepirudin therapy, HIT diagnostic tests, and clinically significant adverse events. Thirty-four patients received argatroban, 42 received lepirudin. Mean+/-SD doses of argatroban and lepirudin were 1.2+/-0.9 microg/kg/minute and 0.09+/-0.11 mg/kg/hour, respectively; both were 40% lower than the recommended doses. Mean duration of therapy was 10+/-9 days. Supratherapeutic activated partial thromboplastin times were observed in 30 (39%), 10 (13%) , and six (8%) of 76 patients on days 1, 2, and 3, respectively (p<0.0001). Clinically significant bleeding occurred in 6% of patients receiving argatroban and in 5% of those receiving lepirudin (p=0.99); all patients had an activated partial thromboplastin time of longer than 100 seconds. Although platelet-aggregation tests were ordered in 55 (72%) of 76 patients, they were not useful in 16 (29%) because of equivocal or contradictory results. Due to supratherapeutic activated partial thromboplastin times, our patients often required doses of argatroban and lepirudin lower than those usually recommended. Thus, direct thrombin inhibitors should be started at low initial doses and titrated to target activated partial thromboplastin times to achieve appropriate efficacy and to avoid increasing the risk of bleeding. Platelet-aggregation tests were least useful for evaluating HIT. Appropriate diagnostic strategies should be used to avoid unnecessary drug use.Keywords
This publication has 26 references indexed in Scilit:
- Effect of Direct Thrombin Inhibitors, Bivalirudin, Lepirudin, and Argatroban, on Prothrombin Time and INR ValuesAmerican Journal of Clinical Pathology, 2004
- Hirudin In Renal InsufficiencySeminars in Thrombosis and Hemostasis, 2002
- ArgatrobanDrugs, 2001
- Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight HeparinCirculation, 1999
- Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- Heparin-Induced ThrombocytopeniaDrug Safety, 1997
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- AnnotationBritish Journal of Haematology, 1995
- Different platelet specificities of heparin‐dependent platelet aggregating factors in heparin‐associated immune thrombocytopeniaBritish Journal of Haematology, 1986
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976